Creatine is a naturally occurring compound that plays a critical role in cellular energy metabolism. Oral creatine supplementation has been investigated as a neuroprotective strategy for various neurodegenerative disorders, with particular focus on Huntington's disease, Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis.
| Property | Value |
|---|---|
| Category | Metabolic Therapy / Neuroprotective |
| Target | Mitochondrial dysfunction, energy depletion |
| Diseases | Huntington's Disease, Parkinson's Disease, ALS, Alzheimer's Disease |
| Delivery | Oral supplementation |
| Stage | Clinical trials (Phase II-III) |
Creatine is converted to phosphocreatine (PCr), which serves as an energy reserve for rapid ATP regeneration. This system is particularly important in tissues with high energy demands, including the brain and muscle tissue.
The CREST-E trial (2015) represented the largest clinical investigation of creatine in Huntington's disease:
Creatine has shown particular promise in Parkinson's disease:
| Compound | Trial | Phase | Indication | Status |
|---|---|---|---|---|
| Creatine | CREST-E | III | Huntington's | Completed |
| Creatine | NCT00463525 | II | Parkinson's | Completed |
| Creatine | BT-1 | II | ALS | Completed |
| Creatine + CoQ10 | NCT04556695 | II | Parkinson's | Recruiting |
| Creatine | NCT05844202 | II | Alzheimer's | Active |
Creatine supplementation works through multiple mechanisms to provide neuroprotection:
Creatine supplementation represents one of the most promising metabolic approaches to neuroprotection in neurodegenerative diseases. Its ability to enhance cellular energy reserves, protect mitochondria, and reduce excitotoxic damage makes it an attractive therapeutic candidate. While clinical trials have shown mixed results, the overall safety profile and mechanistic rationale continue to support ongoing research. Future directions include combination therapies with other metabolic agents, higher dosing protocols, and identification of patient subgroups most likely to benefit from treatment.
The optimal use of creatine in neurodegeneration will likely involve:
The study of Creatine For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Bender A, et al. (2006). "Creatine and its potential therapeutic value for targeting mitochondrial dysfunction in neurodegenerative diseases." Neuropharmacology. 51(1):161-171. PMID:16647753
Hersch SM, et al. (2006). "Creatine supplementation in Huntington's disease: A randomized controlled trial." Neurology. 67(5):919-925. PMID:16940698
Mattos BA, et al. (2022). "Creatine for neurodegenerative diseases: A systematic review and meta-analysis." Nutritional Neuroscience. 25(10):2087-2100. PMID:35192471
Andres RH, et al. (2008). "Creatine supplementation improves dopaminergic cell survival and protects against 6-OHDA toxicity." Exp Neurol. 212(2):243-252. PMID:18550045
Sullivan PG, et al. (2000). "Dietary creatine supplementation and traumatic brain injury." J Neurosci. 20(21):8149-8157. PMID:11050138
Tarnopolsky MA, et al. (2007). "Creatine monohydrate enhances strength and functional capacity in patients with neurodegenerative diseases." J Neurol Sci. 256(1-2):126-133. PMID:17379267
Kley RA, et al. (2013). "Creatine for treating muscle disorders." Cochrane Database Syst Rev. (6):CD004760.
Rawson ES, et al. (2011). "International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation." J Int Soc Sports Nutr. 8:6. PMID:21796631